[en] BACKGROUND AND STUDY AIMS: Anti-TNF monoclonal antibodies are a cornerstone in the treatment of Crohn's disease. Prospective data on switching from the subcutaneous and human adalimumab (ADM) to the intravenous and chimeric infliximab (IFX) are scarce. PATIENTS AND METHODS: In this prospective, observational, multicentre cohort study we included 21 patients with loss of response to ADM despite at least 4 consecutive weekly injections. Clinical response (CDAI drop>/=70 points) and remission (CDAI
Disciplines :
Gastroenterology & hepatology
Author, co-author :
Peeters, H.
Louis, Edouard ; Université de Liège - ULiège > Département des sciences cliniques > Hépato-gastroentérologie
Targan S.R., Hanauer S.B., van Deventer S.J., Mayer L., Present D.H., Braakman T., et al. A short-term study of chimeric monoclonal antibody cA2 to tumor necrosis factor alpha for Crohn’s disease. Crohn’s Disease cA2 Study Group. N. Engl. J. Med., 1997, 337(15): 1029-35.
Hanauer S.B., Feagan B.G., Lichtenstein G.R., Mayer L.F., Schreiber S., Colombel J.F., et al. ACCENT I Study Group. Maintenance infliximab for Crohn’s disease: the ACCENT I randomised trial. Lancet, 2002, 359 (9317): 1541-9.
Sands B.E., Anderson F.H., Bernstein C.N., Chey W.Y., Feagan B.G., Fedorak R.N., et al. Infliximab maintenance therapy for fistulizing Crohn’s disease. N. Engl. J. Med., 2004, 350 (9): 876-85.
Hanauer S.B., Sandborn W.J., Rutgeerts P., Fedorak R.N., Lukas M., MacIntosh D., et al. Human anti-tumor necrosis factor monoclonal antibody (adalimumab) in Crohn’s disease: the CLASSIC-I trial. Gastroenterology, 2006, 130 (2): 323-33.
Sandborn W.J., Hanauer S.B., Rutgeerts P., Fedorak R.N., Lukas M., MacIntosh D.G., et al. Adalimumab for maintenance treatment of Crohn’s disease: results of the CLASSIC II trial. Gut, 2007, 56 (9): 1232-9.
Ben-Horin S., Chowers Y. Review article: loss of response to anti-TNF treatments in Crohn’s disease. Aliment. Pharmacol. Ther., 2011, 33 (9): 987-95.
Gisbert J.P., Panés J. Loss of response and requirement of infliximab dose intensification in Crohn’s disease: a review. Am. J. Gastroenterol., 2009, 104 (3): 760-7.
Sandborn W.J., Rutgeerts P., Enns R., Hanauer S.B., Colombel J.F., Panaccione R., et al. Adalimumab induction therapy for Crohn disease previously treated with infliximab: a randomized trial. Ann. Intern. Med., 2007, 146 (12): 829-38.
Colombel J.F., Sandborn W.J., Rutgeerts P., Enns R., Hanauer S.B., Panaccione R., et al. Adalimumab for maintenance of clinical response and remission in patients with Crohn’s disease: the CHARM trial. Gastroenterology, 2007, 132 (1): 52-65.
Hoentjen F., Haarhuis B.J., Drenth J.P., de Jong D.J. Elective switching from infliximab to adalimumab in stable Crohn’s disease. Inflamm. Bowel Dis., 2013, 19 (4): 761-6.
Van Assche G., Vermeire S., Ballet V., Gabriels F., Noman M., D’Haens G., et al. Switch to adalimumab in patients with Crohn’s disease controlled by maintenance infliximab: prospective randomised SWITCH trial. Gut, 2012, 61 (2): 229-34.
Billioud V., Sandborn W.J., Peyrin-Biroulet L. Loss of response and need for adalimumab dose intensification in Crohn’s disease: a systematic review. Am. J. Gastroenterol., 2011, 106 (4): 674-84.
Silverberg M.S., Satsangi J., Ahmad T., Arnott I.D., Bernstein C.N., Brant S.R., et al. Toward an integrated clinical, molecular and serological classification of inflammatory bowel disease: report of a Working Party of the 2005 Montreal World Congress of Gastroenterology. Can. J. Gastroenterol., 2005, 19, Suppl A: 5A-36A.
Bian S., Stappen T.V., Baert F., Compernolle G., Brouwers E., Tops S., et al. Generation and characterization of a unique panel of anti-adalimumab specific antibodies and their application in therapeutic drug monitoring assays. J. Pharm. Biomed. Anal., 2016, 125: 62-7.
Gils A., Vande Casteele N., Poppe R., Van de Wouwer M., Compernolle G., Peeters M., et al. Development of a universal antiadalimumab antibody standard for interlaboratory harmonization. Ther. Drug Monit., 2014, 36 (5): 669-73.
Van Stappen T., Billiet T., Vande Casteele N., Compernolle G., Brouwers E., Vermeire S., et al. An Optimized Anti-infliximab Bridging Enzyme-linked Immunosorbent Assay for Harmonization of Antiinfliximab Antibody Titers in Patients with Inflammatory Bowel Diseases. Inflamm. Bowel Dis., 2015, 21 (9): 2172-7.
Roblin X., Marotte H., Rinaudo M., Del Tedesco E., Moreau A., Phelip J.M., et al. Association between pharmacokinetics of adalimumab and mucosal healing in patients with inflammatory bowel diseases. Clin. Gastroenterol. Hepatol., 2014, 12 (1): 80-4.
Papamichael K., Cheifetz A.S. Higher Adalimumab Drug Levels Are Associated with Mucosal Healing in Patients with Crohn’s Disease. J. Crohns Colitis., 2016, 10 (5): 507-9.
Matsuoka K., Kanai T. Mechanism and therapeutic strategy of secondary failure to anti-tumor necrosis factor-α monoclonal antibody treatment for Crohn’s disease. Digestion, 2013, 88 (1): 17-9.
Gisbert J.P., Marín A.C., McNicholl A.G., Chaparro M. Systematic review with meta-analysis: the efficacy of a second anti-TNF in patients with inflammatory bowel disease whose previous anti-TNF treatment has failed. Aliment. Pharmacol. Ther., 2015, 41 (7): 613-23.
De Boer N.K.h, Löwenberg M., Hoentjen F. Management of Crohn’s disease in poor responders to adalimumab. Clin. Exp. Gastroenterol., 2014, 7: 83-92.
Hiroz P., Vavricka S.R., Fournier N., Safroneeva E., Pittet V., Rogler G., et al. Swiss Inflammatory Bowel Diseases Cohort Study Group. Analysis of TNF-antagonist switch over time and associated risk factors in the Swiss Inflammatory Bowel Disease Cohort. Scand. J. Gastroenterol., 2014, 49 (10): 1207-18.
Chaparro M., Andreu M., Barreiro-de Acosta M., García-Planella E., Ricart E., Domènech E., et al. Effectiveness of infliximab after adalimumab failure in Crohn’s disease. World J. Gastroenterol., 2012, 18 (37): 5219-24.
Roblin X., Rinaudo M., Del Tedesco E., Phelip J.M., Genin C., Peyrin-Biroulet L., et al. Development of an algorithm incorporating pharmacokinetics of adalimumab in inflammatory bowel diseases. Am. J. Gastroenterol.,2014, 109 (8): 1250-6.
Sandborn W.J., Hanauer S., Loftus E.V. Jr., Tremaine W.J., Kane S., Cohen R., et al. An open-label study of the human anti-TNF monoclonal antibody adalimumab in subjects with prior loss of response or intolerance to infliximab for Crohn’s disease. Am. J. Gastroenterol., 2004, 99(10): 1984-9.
Da W., Zhu J., Wang L., Lu Y. Adalimumab for Crohn’s disease after infliximab treatment failure: a systematic review. Eur. J. Gastroenterol. Hepatol., 2013, 25 (8): 885-91.
Ma C., Panaccione R., Heitman S.J., Devlin S.M., Ghosh S., Kaplan G.G. Systematic review: the short-term and long-term efficacy of adalimumab following discontinuation of infliximab. Aliment. Pharmacol. Ther., 2009, 30 (10): 977-86.
Regueiro M., Siemanowski B., Kip K.E., Plevy S. Infliximab dose intensification in Crohn’s disease. Inflamm. Bowel Dis., 2007, 13 (9): 1093-9.
Lam M.C., Lee T., Atkinson K., Bressler B. Time of infliximab therapy initiation and dose escalation in Crohn’s disease. World J. Gastroenterol., 2014, 20 (1): 214-8.
Colombel J.F., Sandborn W.J., Reinisch W., Mantzaris G.J., Kornbluth A., Rachmilewitz D., et al. SONIC Study Group. Infliximab, azathioprine, or combination therapy for Crohn’s disease. N. Engl. J. Med., 2010, 362 (15): 1383-95.
Baert F., Noman M., Vermeire S., Van Assche G., D’ Haens G., Carbonez A., et al. Influence of immunogenicity on the long-term efficacy of infliximab in Crohn’s disease. N. Engl. J. Med., 2003, 348 (7): 601-8.
Yanai H., Lichtenstein L., Assa A., Mazor Y., Weiss B., Levine A., et al. Levels of drug and antidrug antibodies are associated with outcome of interventions after loss of response to infliximab or adalimumab. Clin. Gastroenterol. Hepatol., 2015, 13 (3): 522-30.
Afif W., Loftus E.V. Jr, Faubion W.A., Kane S.V., Bruining D.H., Hanson K.A., et al. Clinical utility of measuring infliximab and human anti-chimeric antibody concentrations in patients with inflammatory bowel disease. Am. J. Gastroenterol., 2010, 105 (5): 1133-9.
Vande Casteele N., Gils A., Singh S., Ohrmund L., Hauenstein S., Rutgeerts P., et al. Antibody response to infliximab and its impact on pharmacokinetics can be transient. Am. J. Gastroenterol., 2013, 108 (6): 962-71.
